{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T10:00:42Z","timestamp":1789207242630,"version":"build-2803163510"},"reference-count":31,"publisher":"Oxford University Press (OUP)","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,8,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Paecilomyces variotii is an opportunistic mold that causes pulmonary infections in immunosuppressed humans that are often treated with triazole therapy. Lupus nephritis is a major cause of progressive kidney disease in patients with systemic lupus erythematosus, often requiring cyclophosphamide-based therapies. Triazole-cyclophosphamide co-administration is challenging as triazoles increase cyclophosphamide concentrations, which can worsen cyclophosphamide toxicity. We describe herein a patient with Paecilomyces variotii pneumonia and concomitant lupus nephritis who was successfully treated with posaconazole and echinocandin-bridged interruptions to allow for cyclophosphamide therapy. This regimen was well-tolerated without cyclophosphamide toxicity and achieved improvements in both fungal pneumonia and renal function.<\/jats:p>","DOI":"10.1093\/ofid\/ofad410","type":"journal-article","created":{"date-parts":[[2023,8,2]],"date-time":"2023-08-02T12:48:26Z","timestamp":1690980506000},"source":"Crossref","is-referenced-by-count":3,"title":["Successful Treatment of <i>Paecilomyces variotii<\/i> Pneumonia and Lupus Nephritis With Posaconazole-Cyclophosphamide Co-administration Without Drug Interaction\u2013Induced Toxicity"],"prefix":"10.1093","volume":"10","author":[{"given":"Joseph","family":"Pechacek","sequence":"first","affiliation":[{"name":"Fungal Pathogenesis Section, National Institute of Allergy and Infectious Diseases, National Institutes of Health , Bethesda, Maryland , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taura","family":"Webb","sequence":"additional","affiliation":[{"name":"Fungal Pathogenesis Section, National Institute of Allergy and Infectious Diseases, National Institutes of Health , Bethesda, Maryland , USA"},{"name":"Kidney Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health , Bethesda, Maryland , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elise M N","family":"Ferr\u00e9","sequence":"additional","affiliation":[{"name":"Fungal Pathogenesis Section, National Institute of Allergy and Infectious Diseases, National Institutes of Health , Bethesda, Maryland , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica M","family":"Schmitt","sequence":"additional","affiliation":[{"name":"Fungal Pathogenesis Section, National Institute of Allergy and Infectious Diseases, National Institutes of Health , Bethesda, Maryland , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"DiMaggio","sequence":"additional","affiliation":[{"name":"Fungal Pathogenesis Section, National Institute of Allergy and Infectious Diseases, National Institutes of Health , Bethesda, Maryland , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dale","family":"Kobrin","sequence":"additional","affiliation":[{"name":"Lupus Clinical Trials Unit, National Institute of Arthritis and Musculoskeletal and Skin Disease, National Institutes of Health , Bethesda, Maryland , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suraj","family":"Rajasimhan","sequence":"additional","affiliation":[{"name":"Pharmacy Department, National Institutes of Health Clinical Center , Bethesda, Maryland , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ben","family":"Colton","sequence":"additional","affiliation":[{"name":"Pharmacy Department, National Institutes of Health Clinical Center , Bethesda, Maryland , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2002-4339","authenticated-orcid":false,"given":"Russell E","family":"Lewis","sequence":"additional","affiliation":[{"name":"Dipartimento di Medicine Molecolare, University of Padua , Padua , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Andes","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Medical Microbiology and Immunology, Department of Medicine, University of Wisconsin\u2013Madison , Madison, Wisconsin , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandro","family":"Herrera","sequence":"additional","affiliation":[{"name":"Virtua Infectious Disease, Virtua Voorhees, Virtua Medical Group , Vorhees, New Jersey , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dima","family":"Hammoud","sequence":"additional","affiliation":[{"name":"Radiology and Imaging Sciences, National Institutes of Health Clinical Center , Bethesda, Maryland , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seyedmojtaba","family":"Seyedmousavi","sequence":"additional","affiliation":[{"name":"Microbiology Service, Department of Laboratory Medicine, Clinical Center, National Institutes of Health , Bethesda, Maryland , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarfaraz","family":"Hasni","sequence":"additional","affiliation":[{"name":"Lupus Clinical Trials Unit, National Institute of Arthritis and Musculoskeletal and Skin Disease, National Institutes of Health , Bethesda, Maryland , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Bola\u00f1os","sequence":"additional","affiliation":[{"name":"Kidney Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health , Bethesda, Maryland , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Behdad","family":"Afzali","sequence":"additional","affiliation":[{"name":"Kidney Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health , Bethesda, Maryland , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4994-9500","authenticated-orcid":false,"given":"Michail S","family":"Lionakis","sequence":"additional","affiliation":[{"name":"Fungal Pathogenesis Section, National Institute of Allergy and Infectious Diseases, National Institutes of Health , Bethesda, Maryland , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,8,2]]},"reference":[{"key":"2023080911534020600_ofad410-B1","doi-asserted-by":"crossref","first-page":"2754","DOI":"10.1128\/JCM.00764-10","article-title":"Identification of Paecilomyces variotii in clinical samples and settings","volume":"48","author":"Houbraken","year":"2010","journal-title":"J Clin Microbiol"},{"key":"2023080911534020600_ofad410-B2","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1111\/myc.12525","article-title":"Treatment of Paecilomyces variotii pneumonia with posaconazole: case report and literature review","volume":"59","author":"Feldman","year":"2016","journal-title":"Mycoses"},{"key":"2023080911534020600_ofad410-B3","article-title":"A case of pulmonary mycetoma caused by Paecilomyces variotii","volume":"6","author":"Marques","year":"2019","journal-title":"Eur J Case Rep Intern Med"},{"key":"2023080911534020600_ofad410-B4","doi-asserted-by":"crossref","first-page":"684","DOI":"10.3390\/jof8070684","article-title":"Species identification and in vitro antifungal susceptibility of Paecilomyces\/Purpureocillium species isolated from clinical respiratory samples: a multicenter study","volume":"8","author":"Monpierre","year":"2022","journal-title":"J Fungi (Basel)"},{"key":"2023080911534020600_ofad410-B5","article-title":"Paecilomyces variotii as an emergent pathogenic agent of pneumonia","volume":"2013","author":"Steiner","year":"2013","journal-title":"Case Rep Infect Dis"},{"key":"2023080911534020600_ofad410-B6","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/S0022-5223(19)40222-5","article-title":"Paecilomyces varioti endocarditis on a prosthetic aortic valve","volume":"71","author":"McClellan","year":"1976","journal-title":"J Thorac Cardiovasc Surg"},{"key":"2023080911534020600_ofad410-B7","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/1469-0691.12126","article-title":"Mycotic keratitis: epidemiology, diagnosis and management","volume":"19","author":"Thomas","year":"2013","journal-title":"Clin Microbiol Infect"},{"key":"2023080911534020600_ofad410-B8","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.mycmed.2017.02.001","article-title":"Paecilomyces variotii peritonitis in a patient on continuous ambulatory peritoneal dialysis","volume":"27","author":"Uzunoglu","year":"2017","journal-title":"J Mycol Med"},{"key":"2023080911534020600_ofad410-B9","doi-asserted-by":"crossref","first-page":"e93","DOI":"10.1016\/j.jinf.2004.09.006","article-title":"Paecilomyces variotii fungemia in a patient with multiple myeloma: case report and literature review","volume":"51","author":"Salle","year":"2005","journal-title":"J Infect"},{"key":"2023080911534020600_ofad410-B10","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofaa166","article-title":"Disseminated intravascular infection caused by Paecilomyces variotii: case report and review of the literature","volume":"7","author":"Lazarus","year":"2020","journal-title":"Open Forum Infect Dis"},{"key":"2023080911534020600_ofad410-B11","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1007\/s10096-005-0013-y","article-title":"Pulmonary mycetoma caused by an atypical isolate of Paecilomyces species in an immunocompetent individual: case report and literature review of Paecilomyces lung infections","volume":"24","author":"Gutierrez","year":"2005","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"2023080911534020600_ofad410-B12","doi-asserted-by":"crossref","first-page":"379","DOI":"10.2165\/11319340-000000000-00000","article-title":"Pharmacokinetic\/pharmacodynamic profile of posaconazole","volume":"49","author":"Li","year":"2010","journal-title":"Clin Pharmacokinet"},{"key":"2023080911534020600_ofad410-B13","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1053\/j.ajkd.2019.10.017","article-title":"Update on lupus nephritis: core curriculum 2020","volume":"76","author":"Parikh","year":"2020","journal-title":"Am J Kidney Dis"},{"key":"2023080911534020600_ofad410-B14","doi-asserted-by":"crossref","first-page":"825","DOI":"10.2215\/CJN.05780616","article-title":"Update on lupus nephritis","volume":"12","author":"Almaani","year":"2017","journal-title":"Clin J Am Soc Nephrol"},{"key":"2023080911534020600_ofad410-B15","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1056\/NEJM198603063141004","article-title":"Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs","volume":"314","author":"Austin","year":"1986","journal-title":"N Engl J Med"},{"key":"2023080911534020600_ofad410-B16","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/j.kint.2021.05.015","article-title":"Executive summary of the KDIGO 2021 guideline for the management of glomerular diseases","volume":"100","author":"Rovin","year":"2021","journal-title":"Kidney Int"},{"key":"2023080911534020600_ofad410-B17","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1182\/blood-2003-07-2512","article-title":"Cyclophosphamide metabolism is affected by azole antifungals","volume":"103","author":"Marr","year":"2004","journal-title":"Blood"},{"key":"2023080911534020600_ofad410-B18","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1182\/blood-2003-08-2644","article-title":"Itraconazole versus fluconazole for prevention of fungal infections in patients receiving allogeneic stem cell transplants","volume":"103","author":"Marr","year":"2004","journal-title":"Blood"},{"key":"2023080911534020600_ofad410-B19","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1177\/1060028019896894","article-title":"The influence of different triazole antifungal agents on the pharmacokinetics of cyclophosphamide","volume":"54","author":"Cai","year":"2020","journal-title":"Ann Pharmacother"},{"key":"2023080911534020600_ofad410-B20","volume-title":"Reference method for broth dilution antifungal susceptibility testing of filamentous fungi","author":"Clinical and Laboratory Standards Institute (CLSI)","year":"2017","edition":"3rd ed"},{"key":"2023080911534020600_ofad410-B21","doi-asserted-by":"crossref","DOI":"10.1016\/j.jsbmb.2020.105605","article-title":"Molecular mechanisms of posaconazole- and itraconazole-induced pseudohyperaldosteronism and assessment of other systemically used azole antifungals","volume":"199","author":"Beck","year":"2020","journal-title":"J Steroid Biochem Mol Biol"},{"key":"2023080911534020600_ofad410-B22","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2019.104311","article-title":"Drug-induced endocrine blood pressure elevation","volume":"154","author":"Beck","year":"2020","journal-title":"Pharmacol Res"},{"key":"2023080911534020600_ofad410-B23","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.2165\/00003088-200544110-00003","article-title":"Clinical pharmacokinetics of cyclophosphamide","volume":"44","author":"de Jonge","year":"2005","journal-title":"Clin Pharmacokinet"},{"key":"2023080911534020600_ofad410-B24","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1111\/ejh.12368","article-title":"Feasibility and effectiveness of posaconazole prophylaxis in combination with micafungin bridging for patients undergoing allogeneic stem cell transplantation: a 6-yr analysis from the Cologne cohort for neutropenic patients","volume":"93","author":"Vehreschild","year":"2014","journal-title":"Eur J Haematol"},{"key":"2023080911534020600_ofad410-B25","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00760-17","article-title":"In vivo 11\u03b2-hydroxysteroid dehydrogenase inhibition in posaconazole-induced hypertension and hypokalemia","volume":"61","author":"Thompson","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2023080911534020600_ofad410-B26","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1093\/cid\/ciz944","article-title":"Azole-associated pseudohyperaldosteronism: a class effect or azole-specific?","volume":"71","author":"Dipippo","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2023080911534020600_ofad410-B27","doi-asserted-by":"crossref","first-page":"2768","DOI":"10.1093\/cid\/ciaa119","article-title":"Posaconazole-induced pseudohyperaldosteronism manifesting with nephrotic-range proteinuria","volume":"71","author":"Parker","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2023080911534020600_ofad410-B28","doi-asserted-by":"crossref","first-page":"2926","DOI":"10.1128\/AAC.00538-08","article-title":"Susceptibility testing and molecular classification of Paecilomyces spp","volume":"52","author":"Castelli","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"2023080911534020600_ofad410-B29","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1093\/jac\/dkp355","article-title":"An EORTC phase II study of caspofungin as first-line therapy of invasive aspergillosis in haematological patients","volume":"64","author":"Viscoli","year":"2009","journal-title":"J Antimicrob Chemother"},{"issue":"Suppl 4","key":"2023080911534020600_ofad410-B30","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1185\/03007995.2012.761135","article-title":"Optimizing antifungal choice and administration","volume":"29","author":"Andes","year":"2013","journal-title":"Curr Med Res Opin"},{"key":"2023080911534020600_ofad410-B31","first-page":"1621","article-title":"Breakthrough invasive mold infections in the hematology patient: current concepts and future directions","volume":"67","author":"Lionakis","year":"2018","journal-title":"Clin Infect Dis"}],"container-title":["Open Forum Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ofid\/advance-article-pdf\/doi\/10.1093\/ofid\/ofad410\/51023396\/ofad410.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/10\/8\/ofad410\/51075417\/ofad410.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/10\/8\/ofad410\/51075417\/ofad410.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,9]],"date-time":"2023-08-09T11:54:28Z","timestamp":1691582068000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ofid\/article\/doi\/10.1093\/ofid\/ofad410\/7235476"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,1]]},"references-count":31,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2023,8,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ofid\/ofad410","relation":{},"ISSN":["2328-8957"],"issn-type":[{"value":"2328-8957","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,8]]},"published":{"date-parts":[[2023,8,1]]},"article-number":"ofad410"}}